While CEA itself has poor sensitivity (45%) for pancreatic cancer [80], the simultaneous elevation of both CA19-9 (>75 U/mL) and CEA (>5 ng/mL) dramatically increases the specificity for pancreatic cancer to as high as 99%, albeit at the cost of reduced sensitivity [17]. Here, CEACAM5 is linked to familial pancreatic carcinoma.